Saroj Kumar Shrestha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Saroj Kumar Shrestha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Yunjo Soh
Department of Pharmacology, School of Pharmacy Jeonbuk National University Jeonju Republic of Korea
6 shared publications - Hyoungsu Kim
Department of Pharmacy and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon 16499, Republic of Korea
2 shared publications - Liang Li
Department of Dental Pharmacology, School of Dentistry, Chonbuk National University, Jeonju 561-756, Republic of Korea
2 shared publications - Ming Yang
Department of Periodontology, School of Dentistry, Jeonbuk National University, Jeonju, Korea
2 shared publications - William H. Gerwick
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA 92093, USA
2 shared publications - Hyukjae Choi
College of Pharmacy, Yeungnam University, Gyeongsan-si 38541, Gyeongsangbukdo, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 7 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1207
Kalkitoxin: A Potent Suppressor of Distant Breast Cancer Metastasis
Bone metastasis resulting from advanced breast cancer causes osteolysis and increases mortality in patients. Kalkitoxin (KT), a lipopeptide toxin derived from the marine cyanobacterium Moorena producens (previously Lyngbya majuscula), has an anti-metastatic effect on cancer cells. We verified that KT suppressed cancer cell migration and invasion in vitro and in animal models in the present study. We confirmed that KT suppressed osteoclast-soup-derived MDA-MB-231 cell invasion in vitro and induced osteolysis in a mouse model, possibly enhancing/inhibiting metastasis markers. Furthermore, KT inhibits CXCL5 and CXCR2 expression, suppressing the secondary growth of breast cancer cells on the bone, brain, and lungs. The breast-cancer-induced osteolysis in the mouse model further reveals that KT plays a protective role, judging by micro-computed tomography and immunohistochemistry. We report for the first time the novel suppressive effects of KT on cancer cell migration and invasion in vitro and on MDA-MB-231-induced bone loss in vivo. These results suggest that KT may be a potential therapeutic drug for the treatment of breast cancer metastasis.
- 7 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1207
Open AccessKalkitoxin: A Potent Suppressor of Distant Breast Cancer Metastasis
Bone metastasis resulting from advanced breast cancer causes osteolysis and increases mortality in patients. Kalkitoxin (KT), a lipopeptide toxin derived from the marine cyanobacterium Moorena producens (previously Lyngbya majuscula), has an anti-metastatic effect on cancer cells. We verified that KT suppressed cancer cell migration and invasion in vitro and in animal models in the present study. We confirmed that KT suppressed osteoclast-soup-derived MDA-MB-231 cell invasion in vitro and induced osteolysis in a mouse model, possibly enhancing/inhibiting metastasis markers. Furthermore, KT inhibits CXCL5 and CXCR2 expression, suppressing the secondary growth of breast cancer cells on the bone, brain, and lungs. The breast-cancer-induced osteolysis in the mouse model further reveals that KT plays a protective role, judging by micro-computed tomography and immunohistochemistry. We report for the first time the novel suppressive effects of KT on cancer cell migration and invasion in vitro and on MDA-MB-231-induced bone loss in vivo. These results suggest that KT may be a potential therapeutic drug for the treatment of breast cancer metastasis.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Veterinary Science
- Vol. 24 (5) , e69
Kalkitoxin attenuates calcification of vascular smooth muscle cells via RUNX-2 signaling pathways
Shrestha SK, et al. J Vet Sci. 2023 Aug;24:e69. https://doi.org/10.4142/jvs.23148
- 1 January 2023
- Published by XMLink in Journal of Veterinary Science
- Vol. 24 (5) , e69
Open AccessKalkitoxin attenuates calcification of vascular smooth muscle cells via RUNX-2 signaling pathways
Shrestha SK, et al. J Vet Sci. 2023 Aug;24:e69. https://doi.org/10.4142/jvs.23148
- Open Access
- 9 May 2022
- Published by XMLink in Journal of Periodontal & Implant Science
- Vol. 52 (5) , 383-393
Effects of aloe-emodin on alveolar bone in Porphyromonas gingivalis-induced periodontitis rat model: a pilot study
Yang M, et al. J Periodontal Implant Sci. 2022 May;52:e18. https://doi.org/10.5051/jpis.2104060203
- 9 May 2022
- Published by XMLink in Journal of Periodontal & Implant Science
- Vol. 52 (5) , 383-393
Open AccessEffects of aloe-emodin on alveolar bone in Porphyromonas gingivalis-induced periodontitis rat model: a pilot study
Yang M, et al. J Periodontal Implant Sci. 2022 May;52:e18. https://doi.org/10.5051/jpis.2104060203
- Open Access
- 11 April 2022
- Published by XMLink in Journal of Veterinary Science
- Vol. 23 (4) , e47
Aster saponin A2inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signaling pathway
Su XD, et al. J Vet Sci. 2022 Apr;23(4):e47. https://doi.org/10.4142/jvs.21246
- 11 April 2022
- Published by XMLink in Journal of Veterinary Science
- Vol. 23 (4) , e47
Open AccessAster saponin A2inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signaling pathway
Su XD, et al. J Vet Sci. 2022 Apr;23(4):e47. https://doi.org/10.4142/jvs.21246
- Open Access
- 25 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2303
Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss
Osteoclasts, bone-specified multinucleated cells produced by monocyte/macrophage, are involved in numerous bone destructive diseases such as arthritis, osteoporosis, and inflammation-induced bone loss. The osteoclast differentiation mechanism suggests a possible strategy to treat bone diseases. In this regard, we recently examined the in vivo impact of kalkitoxin (KT), a marine product obtained from the marine cyanobacterium Moorena producens (previously Lyngbya majuscula), on the macrophage colony-stimulating factor (M-CSF) and on the receptor activator of nuclear factor κB ligand (RANKL)-stimulated in vitro osteoclastogenesis and inflammation-mediated bone loss. We have now examined the molecular mechanism of KT in greater detail. KT decreased RANKL-induced bone marrow-derived macrophages (BMMs) tartrate-resistant acid phosphatase (TRAP)-multinucleated cells at a late stage. Likewise, KT suppressed RANKL-induced pit area and actin ring formation in BMM cells. Additionally, KT inhibited several RANKL-induced genes such as cathepsin K, matrix metalloproteinase (MMP-9), TRAP, and dendritic cell-specific transmembrane protein (DC-STAMP). In line with these results, RANKL stimulated both genes and protein expression of c-Fos and nuclear factor of activated T cells (NFATc1), and this was also suppressed by KT. Moreover, KT markedly decreased RANKL-induced p-ERK1/2 and p-JNK pathways at different time points. As a result, KT prevented inflammatory bone loss in mice, such as bone mineral density (BMD) and osteoclast differentiation markers. These experiments demonstrated that KT markedly inhibited osteoclast formation and inflammatory bone loss through NFATc1 and mitogen-activated protein kinase (MAPK) signaling pathways. Therefore, KT may have potential as a treatment for destructive bone diseases.
- 25 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2303
Open AccessKalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss
Osteoclasts, bone-specified multinucleated cells produced by monocyte/macrophage, are involved in numerous bone destructive diseases such as arthritis, osteoporosis, and inflammation-induced bone loss. The osteoclast differentiation mechanism suggests a possible strategy to treat bone diseases. In this regard, we recently examined the in vivo impact of kalkitoxin (KT), a marine product obtained from the marine cyanobacterium Moorena producens (previously Lyngbya majuscula), on the macrophage colony-stimulating factor (M-CSF) and on the receptor activator of nuclear factor κB ligand (RANKL)-stimulated in vitro osteoclastogenesis and inflammation-mediated bone loss. We have now examined the molecular mechanism of KT in greater detail. KT decreased RANKL-induced bone marrow-derived macrophages (BMMs) tartrate-resistant acid phosphatase (TRAP)-multinucleated cells at a late stage. Likewise, KT suppressed RANKL-induced pit area and actin ring formation in BMM cells. Additionally, KT inhibited several RANKL-induced genes such as cathepsin K, matrix metalloproteinase (MMP-9), TRAP, and dendritic cell-specific transmembrane protein (DC-STAMP). In line with these results, RANKL stimulated both genes and protein expression of c-Fos and nuclear factor of activated T cells (NFATc1), and this was also suppressed by KT. Moreover, KT markedly decreased RANKL-induced p-ERK1/2 and p-JNK pathways at different time points. As a result, KT prevented inflammatory bone loss in mice, such as bone mineral density (BMD) and osteoclast differentiation markers. These experiments demonstrated that KT markedly inhibited osteoclast formation and inflammatory bone loss through NFATc1 and mitogen-activated protein kinase (MAPK) signaling pathways. Therefore, KT may have potential as a treatment for destructive bone diseases.
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 883, 173305
Macrolactin A protects against LPS-induced bone loss by regulation of bone remodeling
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 883, 173305
Macrolactin A protects against LPS-induced bone loss by regulation of bone remodeling